NLTX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 gruod. 2023 @ 23:00):

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology...

Stats
Šios dienos apimtis	109 095
Vidutinė apimtis	5 520.00
Rinkos kapitalizacija	8.20M
EPS	$0 ( 2024-03-19 )
Kita pelno data	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.284
ATR14	$0.878 (25.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-16	Woods Robert Keith	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Palekar Rohan	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Noonberg Sarah B.	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Freedland Cory S.	Buy	15 400	Stock Option (Right to Buy)
2024-01-16	Baffi Robert	Buy	15 400	Stock Option (Right to Buy)

INSIDER POWER
75.01
Last 94 transactions
Buy: 7 989 742 \| Sell: 1 025 638

Tūris Koreliacija

Ilgas: -0.32 (neutral)

Trumpas: -0.52 (weak negative)

Signal:(16.09) Neutral

Neoleukin Therapeutics Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Neoleukin Therapeutics Koreliacija - Valiuta/Žaliavos

-0.31
( neutral )

-0.32
( neutral )

0.32
( neutral )

-0.24
( neutral )

0.17
( neutral )

0.18
( neutral )

Neoleukin Therapeutics Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-1.010

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-1.010

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.100

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.640

Financial Reports:

No articles found.

Neoleukin Therapeutics

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.